# Phase II Neoadjuvant in Inflammatory Breast Cancer

> **NCT00756470** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Lapatinib
- **DRUG:** Paclitaxel
- **DRUG:** 5-Fluorouracil (5-FU)
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00756470
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Slow accrual.
- **Last updated:** 2014-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00756470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00756470, "Phase II Neoadjuvant in Inflammatory Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00756470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*